Cardiovascular function in a chronic peritoneal dialysis pediatric population on recombinant human erythropoietin treatment

S. Bassi, G. Montini, A. Edefonti, F. Perfumo, D. Cattarelli, G. Piaggio, V. Fesslova, G. Zacchello, S. Bove

Research output: Contribution to journalArticlepeer-review

Abstract

Anemia, through a hyperkinetic state, is an important contributor to myocardial function impairment. To determine the cardiovascular effects of recombinant human erythropoietin (rHuEPO) therapy, 10 chronic peritoneal dialysis (CPD)-treated anemic children were studied before and during 18 months of treatment. The following parameters were recorded: hemoglobin (Hb) [percent of target level (TL) = x-2 standard deviations of normal Hb values for age and sex], heart rate (HR, beats/minute), mean arterial pressure (MAP, mmHg), end diastolic left ventricular diameter (EDLVD, mm/sm BSA), shortening fraction (SF, percent), and interventricular septal thickness (IVS, mm/sm BSA). Student's t-test for paired data showed (vs time before treatment, TO) a progressive increase in Hb, a progressive decrease in HR, and a progressive increase in MAP. EDLVD progressively decreased, while SF and IVS remained unchanged throughout the study. Regression analysis showed a close correlation between anemia correction and decrease of HR (p

Original languageEnglish
JournalPeritoneal Dialysis International
Volume13
Issue numberSUPPL. 2
Publication statusPublished - 1993

Keywords

  • Chronic anemia
  • Chronic peritoneal dialysis
  • Chronic renal failure
  • Echocardiography
  • Myocardial function
  • Recombinant human erythropoietin

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Cardiovascular function in a chronic peritoneal dialysis pediatric population on recombinant human erythropoietin treatment'. Together they form a unique fingerprint.

Cite this